268 related articles for article (PubMed ID: 16962979)
1. Central role of interleukin-15 in human immunodeficiency virus (HIV)-infected patients with visceral leishmaniasis.
d'Ettorre G; Ceccarelli G; Carnevalini M; Forcina G; Zaffiri L; Massetti AP; Mastroianni CM; Vullo V
Acta Trop; 2006 Aug; 99(1):83-7. PubMed ID: 16962979
[TBL] [Abstract][Full Text] [Related]
2. [Visceral leishmaniasis: a comparative study of patients with and without human immunodeficiency virus infection].
Reus S; Sánchez R; Portilla J; Boix V; Priego M; Merino E; Román F
Enferm Infecc Microbiol Clin; 1999 Dec; 17(10):515-20. PubMed ID: 10650648
[TBL] [Abstract][Full Text] [Related]
3. AA-amyloidosis caused by visceral leishmaniasis in a human immunodeficiency virus-infected patient.
de Vallière S; Mary C; Joneberg JE; Rotman S; Bullani R; Greub G; Gillmore JD; Buffet PA; Tarr PE
Am J Trop Med Hyg; 2009 Aug; 81(2):209-12. PubMed ID: 19635871
[TBL] [Abstract][Full Text] [Related]
4. Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum.
Lachaud L; Bourgeois N; Plourde M; Leprohon P; Bastien P; Ouellette M
Clin Infect Dis; 2009 Jan; 48(2):e16-22. PubMed ID: 19093811
[TBL] [Abstract][Full Text] [Related]
5. Serum chemokine profiles in visceral leishmaniasis, HIV and HIV/ visceral leishmaniasis co-infected Ethiopian patients.
Sisay Z; Berhe N; Petros B; Tegbaru B; Messele T; Hailu A; Wolday D
Ethiop Med J; 2011 Jul; 49(3):179-86. PubMed ID: 21991751
[TBL] [Abstract][Full Text] [Related]
6. Leishmaniases and HIV/AIDS co-infections: review of common features and management experiences.
Ali A
Ethiop Med J; 2002 Apr; 40 Suppl 1():37-49. PubMed ID: 12802830
[TBL] [Abstract][Full Text] [Related]
7. Pre- & post-treatment evaluation of immunological features in Indian visceral leishmaniasis (VL) patients with HIV co-infection.
Sinha PK; Bimal S; Singh SK; Pandey K; Gangopadhyay DN; Bhattacharya SK
Indian J Med Res; 2006 Mar; 123(3):197-202. PubMed ID: 16778304
[TBL] [Abstract][Full Text] [Related]
8. [The clinical and evolutional characteristics of visceral leishmaniasis in patients with HIV infection].
Delgado Fernández M; García Ordoñez MA; Martos Pérez F; Reguera Iglesias JM; Jiménez Oñate F; Colmenero Castillo JD
An Med Interna; 1997 Oct; 14(10):506-10. PubMed ID: 9424140
[TBL] [Abstract][Full Text] [Related]
9. Leishmania donovani vs immunity: T-cells sensitized from Leishmania of one donor may modulate their cytokines pattern on re-stimulation with Leishmania from different donor in visceral leishmaniasis.
Narayan S; Bimal S; Singh SK; Gupta AK; Singh VP; Sinha PK; Das P
Exp Parasitol; 2009 Jan; 121(1):69-75. PubMed ID: 18948098
[TBL] [Abstract][Full Text] [Related]
10. Frequency of visceral leishmaniasis relapses in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy.
Mira JA; Corzo JE; Rivero A; Macias J; De Leon FL; Torre-Cisneros J; Gomez-Mateos J; Jurado R; Pineda JA
Am J Trop Med Hyg; 2004 Mar; 70(3):298-301. PubMed ID: 15031520
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.
Molina I; Falcó V; Crespo M; Riera C; Ribera E; Curran A; Carrio J; Diaz M; Villar del Saz S; Fisa R; López-Chejade P; Ocaña I; Pahissa A
J Antimicrob Chemother; 2007 Oct; 60(4):837-42. PubMed ID: 17684055
[TBL] [Abstract][Full Text] [Related]
12. Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome.
ter Horst R; Collin SM; Ritmeijer K; Bogale A; Davidson RN
Clin Infect Dis; 2008 Jun; 46(11):1702-9. PubMed ID: 18419422
[TBL] [Abstract][Full Text] [Related]
13. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.
Ritmeijer K; Dejenie A; Assefa Y; Hundie TB; Mesure J; Boots G; den Boer M; Davidson RN
Clin Infect Dis; 2006 Aug; 43(3):357-64. PubMed ID: 16804852
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co-infection in northwest Ethiopia.
Hurissa Z; Gebre-Silassie S; Hailu W; Tefera T; Lalloo DG; Cuevas LE; Hailu A
Trop Med Int Health; 2010 Jul; 15(7):848-55. PubMed ID: 20487426
[TBL] [Abstract][Full Text] [Related]
15. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence.
Ritmeijer K; ter Horst R; Chane S; Aderie EM; Piening T; Collin SM; Davidson RN
Clin Infect Dis; 2011 Dec; 53(12):e152-8. PubMed ID: 22016502
[TBL] [Abstract][Full Text] [Related]
16. Clinical and epidemiological features of visceral leishmaniasis and HIV co-infection in fifteen patients from Brazil.
Daher EF; Fonseca PP; Gerhard ES; Leitão TM; Silva Júnior GB
J Parasitol; 2009 Jun; 95(3):652-5. PubMed ID: 19642802
[TBL] [Abstract][Full Text] [Related]
17. Elevated levels of soluble non-classical major histocompatibility class I molecule human leucocyte antigen (HLA)-G in the blood of HIV-infected patients with or without visceral leishmaniasis.
Donaghy L; Gros F; Amiot L; Mary C; Maillard A; Guiguen C; Gangneux JP
Clin Exp Immunol; 2007 Feb; 147(2):236-40. PubMed ID: 17223963
[TBL] [Abstract][Full Text] [Related]
18. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.
López-Vélez R; Videla S; Márquez M; Boix V; Jiménez-Mejías ME; Górgolas M; Arribas JR; Salas A; Laguna F; Sust M; Cañavate C; Alvar J;
J Antimicrob Chemother; 2004 Mar; 53(3):540-3. PubMed ID: 14739148
[TBL] [Abstract][Full Text] [Related]
19. Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India.
Sinha PK; van Griensven J; Pandey K; Kumar N; Verma N; Mahajan R; Kumar P; Kumar R; Das P; Mitra G; Flevaud L; Ferreyra C; Remartinez D; Pece M; Palma PP
Clin Infect Dis; 2011 Oct; 53(7):e91-8. PubMed ID: 21890763
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-10 and the pathogenesis of human visceral leishmaniasis.
Nylén S; Sacks D
Trends Immunol; 2007 Sep; 28(9):378-84. PubMed ID: 17689290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
